Last price update: 17 Apr 24 23:00 GMT
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet’s diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
According to the All-in-one Screener, a Premium feature of GuruFocus, five dividend kings stocks that have high guru ownership as of the third-quarter 2022 13F portfolio filings are Johnson & Johnson ( JNJ , Financial), Proctor & Gamble Co. ( PG , Financial), Coca-Cola Co. ( KO , Financial), AbbVie Inc. ( ABBV , Financial) and PepsiCo Inc. ( PEP , Financial).
Irvine, calif. , jan. 25, 2023 prnewswire allergan AES thetics, an abbvie company ( nyse abbv), today unveiled at the 24 th international master course on aging science ( imcas) world congress its immersive experience ' discover your 360 '.
With juvéderm volux xc, you can receive non surgical jawline augmentation in your AES thetic provider' s office irvine, calif. , jan. 18, 2023 prnewswire today, allergan AES thetics, an abbvie company ( nyse abbv), announced the highly anticipated NAT ional launch of juvéderm volux xc.
The results are clear a scientifically proven PAT h to targeting the appearance of hyperpigmentation and improving skin tone and texture irvine, calif. , jan. 17, 2023 prnewswire today, allergan AES thetics, an abbvie company ( nyse abbv), announces the launch of the long awaited skinmedica even & correct collection.
North chicago, ill. & exton, pa. ( business wire ) abbvie ( nyse abbv) and immunome, inc. ( nasdaq imnm), a CLI NIC al stage biopharmaceutical company that utilizes its human memory b cell platform to discover and develop first in class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody target pairs arising from three specified tumor types using immunome' s discovery engine.
Approval marks fourth indication for vraylar, backed by proven efficacy and well established tolerability as an adjunctive treatment for major depressive disorder ( mdd) with an antidepressant therapy ( adt), showing improvement in symptoms when compared to placebo adt DES igned for specific mood disorders, vraylar is now the first and only dopamine and serotonin partial agonist fda approved for the most common forms of depression – as an adjunctive treatment for mdd and the treatment of depressive episodes associated with bipolar i disorder about one in five u. s. adults will experience mdd during their lifetime, and many of them may have partial response to the treatment with an adt north chicago, ill. , dec. 16, 2022 prnewswire abbvie ( nyse abbv) today announced that the u. s. food and drug administration ( fda) has approved vraylar ( cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder ( mdd) in adults.
If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 submission is based on positive phase 3 study data demonstrating linaclotide (72 MC g) resulted in increases in frequency of spontaneous bowel movements ( sbm) and improved stool consistency in children and adolescents aged 6 to 17 years north chicago, ill. , dec. 16, 2022 prnewswire abbvie ( nyse abbv) today announced that it has submitted a supplemental new drug application ( snda) for linaclotide ( linzess ) to the u. s. food and drug administration ( fda) for the treatment of children and adolescents 6 to 17 years of age with functional constipation ( fc).
Abbvie ranked #1 in biotech sector on the 2022 s& p corporate sustainability assessment north chicago, ill. , dec. 12, 2022 prnewswire abbvie ( nyse abbv) today announced that for the tenth consecutive year, it has been named to the dow jones sustainability world index ( djsi world) and dow jones sustainability north america index ( djsi north america).
Four oral presentations presented at ash highlight data evaluating investigational epcoritamab for the treatment of relapsed refractory ( r r) follicular lymphoma, previously untreated follicular lymphoma, r r diffuse large b cell lymphoma and richter' s SYN drome north chicago, ill. , dec. 11, 2022 prnewswire abbvie ( nyse abbv) today announced data from multiple CLI NIC al trials evaluating epcoritamab ( duobody cd3 xcd20), an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of PAT ients with relapsed refractory ( r r) follicular lymphoma ( fl), previously untreated fl, r r diffuse large b cell lymphoma ( dlbcl), as well as richter' s SYN drome at the 64 th american society of hematology ( ash) annual meeting.
Exploratory analysis from cohort 3 of the phase 2 refine study presented in an oral session at ash north chicago, ill. , dec. 10, 2022 prnewswire abbvie ( nyse abbv) today announced new data from cohort 3 of its phase 2 refine study of investigational navitoclax in combination with ruxolitinib in jak inhibitor naïve PAT ients with myelofibrosis ( mf).
Updated data presented at ash include captivate and glow studies and real world evidence abstracts north chicago, ill. , dec. 10, 2022 prnewswire abbvie ( nyse abbv) today announced new and updated data across CLI NIC al and real world studies in chronic lymphocytic leukemia ( cll).
